Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Cellebrite DI (CLBT) over the last 6 years, with Q3 2025 value amounting to $62.5 million.

  • Cellebrite DI's Accounts Payables rose 1468.69% to $62.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.5 million, marking a year-over-year increase of 1468.69%. This contributed to the annual value of $63.3 million for FY2024, which is 4121.98% up from last year.
  • As of Q3 2025, Cellebrite DI's Accounts Payables stood at $62.5 million, which was up 1468.69% from $68.0 million recorded in Q2 2025.
  • In the past 5 years, Cellebrite DI's Accounts Payables registered a high of $68.0 million during Q2 2025, and its lowest value of $35.6 million during Q2 2023.
  • Over the past 5 years, Cellebrite DI's median Accounts Payables value was $47.5 million (recorded in 2022), while the average stood at $49.1 million.
  • Per our database at Business Quant, Cellebrite DI's Accounts Payables plummeted by 2494.05% in 2023 and then surged by 6083.91% in 2025.
  • Over the past 5 years, Cellebrite DI's Accounts Payables (Quarter) stood at $54.0 million in 2021, then fell by 15.9% to $45.5 million in 2022, then decreased by 1.34% to $44.8 million in 2023, then surged by 41.22% to $63.3 million in 2024, then fell by 1.33% to $62.5 million in 2025.
  • Its Accounts Payables was $62.5 million in Q3 2025, compared to $68.0 million in Q2 2025 and $53.9 million in Q1 2025.